These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29251203)

  • 1. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Hanif A; Wang ES; Thompson JE; Baron JI; Walsh MD; Griffiths EA
    Leuk Lymphoma; 2018 Aug; 59(8):2011-2013. PubMed ID: 29251203
    [No Abstract]   [Full Text] [Related]  

  • 2. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
    Assi R; Kantarjian H; Short NJ; Daver N; Takahashi K; Garcia-Manero G; DiNardo C; Burger J; Cortes J; Jain N; Wierda W; Chamoun S; Konopleva M; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):897-901. PubMed ID: 28927784
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
    Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
    Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.
    Balsat M; Cacheux V; Carre M; Tavernier-Tardy E; Thomas X
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):879-891. PubMed ID: 33016157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.
    Wang D; Pan H; Wang Y
    Leuk Lymphoma; 2017 Jul; 58(7):1733-1735. PubMed ID: 27813432
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the management of Ph-positive ALL.
    Hoelzer D
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):804-5. PubMed ID: 17143248
    [No Abstract]   [Full Text] [Related]  

  • 13. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
    Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Fan S; Wang L; Lu Y; Li Z
    Ann Hematol; 2024 Feb; 103(2):525-532. PubMed ID: 37940719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future management of Ph/BCR-ABL positive ALL.
    Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.